Methylene Blue as Early Adjunct in Septic Shock

Septic shock has a 40% mortality rate in many patients. Methylene blue has been shown in small non-controlled case series to have a benefit. Join host, Geoff Wall, as he reviews a randomized controlled study from Mexico on this novel strategy. The GameChangerMethylene blue is a specific inhibitor of the inducible nitric oxide synthase for indirect pressor effects. Despite confounders, this small study may be a good start for a larger randomized controlled study for methylene blue as early adjunct care in patients with septic shock. Host Geoff Wall, PharmD, BCPS, FCCP, BCGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint Health ReferenceIbarra-Estrada M, Kattan E, Aguilera-González P, et al. Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. Crit Care. 2023 Mar 13;27(1):110. doi: 10.1186/s13054-023-04397-7. PMID: 36915146; PMCID: PMC10010212. Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode) CPE Information Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to: 1. Describe the potential physiologic mechanism of benefit for methylene blue in septic shock 2. Discuss the Ibarra-Estrada et al study limitations 0.05 CEU/0.5 Hr UAN: 0107-0000-23-212-H01-P Initial release date: 6/5/2023 Expiration date: 6/5/2024 Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram